文献速递重症综合管理与镇静镇痛心脑血管急症

脑脊液肝素结合蛋白可改善开颅术后脑膜炎和脑室炎功能结局的评估

Cerebrospinal Fluid Heparin-Binding Protein Improves the Evaluation of Functional Outcomes in Postcraniotomy Meningitis and Ventriculitis.
PubMed 文献 · Neurocrit Care · 2025-06-26
一句话结论在开颅术后脑膜炎或脑室炎患者中,脑脊液肝素结合蛋白识别不良功能结局的AUC为0.86,优于其他脑脊液标志物,且其动态变化有助于评估抗菌治疗疗效。

这项前瞻性观察性队列研究在三级转诊学术医学中心ICU纳入139例开颅术后脑膜炎或脑室炎成人患者,按出院时格拉斯哥结局量表评分分为良好结局组(4-5分,82例)和不良结局组(1-3分,57例)。不良结局组脑脊液肝素结合蛋白水平显著高于良好结局组;良好结局组在抗菌治疗第3-5天肝素结合蛋白较基线显著下降(29 [9-92] ng/mL vs 136 [85-187] ng/mL),而不良结局组是唯一在第3-5天仍保持升高的生物标志物(209 [136-222] ng/mL vs 基线170 [129-200] ng/mL)。肝素结合蛋白识别不良功能结局的AUC最高,为0.86(95%CI 0.78-0.93),校正后OR为1.02(1.00-1.03),p=0.01。作者认为脑脊液肝素结合蛋白是评估此类患者功能结局更准确的候选生物标志物,监测其动力学有助于估计抗菌治疗疗效。

要点

  • 在开颅术后脑膜炎或脑室炎成人患者中,脑脊液肝素结合蛋白识别不良功能结局的AUC为0.86(95%CI 0.78-0.93),为所测标志物中最高。
  • 良好功能结局组抗菌治疗第3-5天脑脊液肝素结合蛋白较基线显著下降:29 [9-92] ng/mL vs 136 [85-187] ng/mL。
  • 不良功能结局组是唯一在抗菌治疗第3-5天脑脊液肝素结合蛋白仍保持升高的组:209 [136-222] ng/mL vs 基线170 [129-200] ng/mL。
  • 脑脊液肝素结合蛋白与患者功能结局显著相关,校正后OR为1.02(1.00-1.03),p=0.01。

适用人群与场景

  • 开颅术后发生脑膜炎或脑室炎的成人患者,收治于三级转诊学术医学中心ICU。

诊断标准与关键阈值

  • 采用格拉斯哥结局量表评分在出院时进行功能结局分组:良好功能结局为4-5分,不良功能结局为1-3分。

研究设计与关键结果

  • 研究类型为前瞻性观察性队列研究,共筛查246例疑似患者,最终纳入139例开颅术后脑膜炎或脑室炎患者,其中良好功能结局82例、不良功能结局57例。
  • 不良功能结局组脑脊液肝素结合蛋白水平显著高于良好功能结局组。
  • 良好功能结局组抗菌治疗第3-5天脑脊液肝素结合蛋白较基线显著下降:29 [9-92] ng/mL vs 136 [85-187] ng/mL。
  • 不良功能结局组是唯一在抗菌治疗第3-5天脑脊液肝素结合蛋白仍保持升高的标志物:209 [136-222] ng/mL vs 基线170 [129-200] ng/mL。
  • 脑脊液肝素结合蛋白识别不良功能结局的AUC为0.86(95%CI 0.78-0.93),为所测标志物中最高。
  • 脑脊液肝素结合蛋白与功能结局显著相关,校正后OR为1.02(1.00-1.03),p=0.01。

证据类型、等级与局限

  • 证据类型:前瞻性观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为脑脊液肝素结合蛋白是评估开颅术后脑膜炎和脑室炎患者功能结局更准确的候选生物标志物。
  • 作者认为监测脑脊液肝素结合蛋白动力学有助于估计抗菌治疗疗效。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The research aimed to explore the role of cerebrospinal fluid heparin-binding protein in estimating the functional outcomes among patients with postcraniotomy meningitis or ventriculitis.

METHODS: Adult patients with meningitis or ventriculitis following craniotomy were eligible for this prospective observational cohort study conducted in the intensive care unit of a tertiary referral academic medical center. Patients were dichotomized by the Glasgow Outcome Scale score as good (4-5) and adverse functional outcome group (1-3) at hospital discharge. Heparin-binding protein, procalcitonin, white blood cell count, glucose, protein, and lactate in cerebrospinal fluid were tested at enrollment and on the 3rd to 5th day of antibiotherapy.

RESULTS: Among 246 suspected participants, 139 with postcraniotomy meningitis or ventriculitis were enrolled in the final analysis, including 82 with good and 57 with adverse functional outcomes. Patients with adverse functional outcomes had significantly higher levels of heparin-binding protein than those with good functional outcomes. The protein descended significantly in patients with good functional outcomes on the 3rd to 5th day of antimicrobial treatment compared with baseline (29 [9-92] ng/mL vs. 136 [85-187] ng/mL). It was the only biomarker that remained high in the adverse functional outcome group on the 3rd to 5th day of treatment (209 [136-222] ng/mL vs. 170 [129-200] ng/mL at baseline). Heparin-binding protein achieved the highest area under the receiver operating characteristic curve of 0.86 (95% confidence interval 0.78-0.93) in recognizing patients with adverse functional outcomes. It was significantly associated with patient functional outcomes with an adjusted odds ratio of 1.02 (1.00-1.03), p = 0.01.

CONCLUSIONS: Cerebrospinal fluid heparin-binding protein is a more accurate candidate biomarker in evaluating functional outcomes among patients with postcraniotomy meningitis and ventriculitis. Monitoring its kinetics helps to estimate antibacterial therapeutic efficacies.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Kong Y, Zhou D, Ye Y, et al. Cerebrospinal Fluid Heparin-Binding Protein Improves the Evaluation of Functional Outcomes in Postcraniotomy Meningitis and Ventriculitis. Neurocrit Care. 2025. PMID: 40571821. doi:10.1007/s12028-025-02224-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。